Close Menu

NEW YORK (360Dx) – Saladax Biomedical said today that it has inked a non-exclusive agreement to license two Alzheimer's diagnostic tests to Siemens Healthineers.

The tests identify the amyloid beta 1-42 and tau biomarkers, two indicators of the early stages of Alzheimer's disease, in cerebrospinal fluid.

Saladax said that under the agreement, it will provide its "proprietary" raw materials, protocols, and intellectual property, and Siemens will commercialize both assays.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Sponsored by
Thermo Fisher Scientific

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines.